AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

About this Study

This study intends to compare the effectiveness of aspirin vs. apixiban (two FDA approved medications that have anti-platelet effects) in preventing the recurrence of cryptogenic (without a known cause) stroke.

Sponsor Protocol ID:NCT03192215
IRB Number:2019-0111
Actively Enrolling
Interventional
Early Phase 1
May 28, 2019
Eligibility Criteria
45 years old
Both Male and Female
No
No
No

Inclusion CriteriaInclusion or exclusion of subjects will not differ based on sex/gender, and the aim is to recruit similar numbers of men and women. The absence of an upper age limit will aid recruitment of women given that they are generally older than men at the time of a first cardiovascular event such as stroke.

Exclusion CriteriaInclusion or exclusion of subjects will not differ based on sex/gender, and the aim is to recruit similar numbers of men and women. The absence of an upper age limit will aid recruitment of women given
that they are generally older than men at the time of a first cardiovascular event such as stroke.

Categories Click category to view its trials.
Neurosciences
Stroke/Traumatic Brain Injury
Participating Locations
University Hospital - UMMC
Contact Information
Contact Name: Andrew Majeste
Phone Number: 601-984-5490
Email: acmajeste@umc.edu
Principal Investigator:Shashank Shekhar
How to participate in our Clinical Trials